Related by context. Frequent words. (Click for all words.) 84 multicenter randomized double 79 Phase III randomized 75 placebo controlled randomized 75 multicenter randomized 74 randomized placebo controlled 72 multicentre 71 randomized double 71 blinded placebo controlled 71 multicenter 70 blind randomized 70 blind randomized placebo 70 prospective randomized 69 prospective observational 69 prospective randomized controlled 69 randomized controlled 68 placebo controlled 67 multicenter clinical 66 Randomized 66 blind randomized controlled 66 randomized clinical 66 double blind placebo 66 active comparator 65 phase IIa 65 randomized Phase III 65 randomized 64 label dose escalation 64 randomized controlled clinical 64 multicenter study 63 Phase 1b clinical 63 dose escalation trial 63 Phase 2b study 63 blind placebo controlled 62 randomized #:# 62 phase IIb 62 substudy 61 Phase 2a clinical 60 single ascending dose 60 randomized controlled trial 60 dose escalation study 59 ATTRACT 59 Phase 2a trial 59 Phase 2b clinical 59 Phase 1b trial 59 Phase Ib 59 Phase IIb trial 59 placebo controlled studies 58 Phase IIa trial 58 Phase 2b trial 58 confirmatory Phase III 58 Phase Ia 58 Phase IIb clinical 58 multiple ascending dose 58 noninferiority 58 Phase IIa clinical 58 Phase IIb 58 phase 2a 57 Phase III clinical 57 randomized Phase 57 pivotal Phase III 57 safety tolerability pharmacokinetics 57 dabigatran etexilate 57 Phase 2a 57 investigational oral 57 Phase 2b 57 Phase IIa 57 Completes Enrollment 57 Phase III 57 pivotal Phase 56 Phase 1b 56 prospective cohort 56 Phase III Trial 56 placebo controlled trials 56 NCT# 56 pharmacodynamics 56 Meta Analysis 56 nab paclitaxel 56 Phase III pivotal 55 mg QD 55 Clinical Trial Results 55 ocular hypertension 55 non inferiority 55 #:#-# [031] 55 Phase 1a 55 dose regimens 55 SCH # 55 J Clin Oncol 55 clinical trial 55 dose escalation 55 Cohort 55 retrospective cohort study 55 TELCYTA 54 peginterferon alfa 2b 54 plus prednisone 54 dose cohorts 54 RESOLUTE 54 Initiates Phase 54 SPIRIT III 54 secondary efficacy endpoints 54 Rosuvastatin 54 Chronic Hepatitis C 54 diabetic neuropathic pain